Bal Pharma Intrinsic Value
Bal Pharma (BALPHARMA) median intrinsic value is ₹44.15 from 9 valuation models (range ₹26–₹170), vs current price ₹85.13 — -48.1% downside (Trading Above Calculated Value), margin of safety -92.8%. Browse BALPHARMA balance sheet details for revenue, profit, balance sheet and cash flow data.
BALPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Bal Pharma intrinsic value across 9 models vs current price ₹85.13 — upside/downside and value range per method. For current market price and key ratios, visit Bal Pharma share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹39.60 | ₹31.68 - ₹47.52 | -53.5% | EPS: ₹1.80, Sector P/E: 22x |
| Book Value Method | asset | ₹96.25 | ₹86.62 - ₹105.88 | +13.1% | Book Value/Share: ₹48.12, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹170.26 | ₹153.23 - ₹187.29 | +100.0% | Revenue/Share: ₹187.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹170.26 | ₹153.23 - ₹187.29 | +100.0% | EBITDA: ₹28.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹116.05 | ₹92.84 - ₹139.26 | +36.3% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹25.54 | ₹22.99 - ₹28.09 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹27.81 | ₹25.03 - ₹30.59 | -67.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹42.56 | ₹38.30 - ₹46.82 | -50.0% | ROE: 5.2%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹44.15 | ₹39.73 - ₹48.57 | -48.1% | EPS: ₹1.80, BVPS: ₹48.12 |
BALPHARMA Intrinsic Value vs Market Price — All Valuation Models
Bal Pharma fair value range ₹26–₹170 vs current market price ₹85.13 across 9 valuation models. Also explore BALPHARMA stock price history to track price trends across different timeframes.
BALPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Bal Pharma median intrinsic value ₹44.15, current price ₹85.13 — Trading Above Calculated Value by 48.1%, margin of safety -92.8%.
What is the intrinsic value of BALPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Bal Pharma (BALPHARMA) is ₹44.15 (median value). With the current market price of ₹85.13, this represents a -48.1% variance from our estimated fair value.
The valuation range spans from ₹25.54 to ₹170.26, indicating ₹25.54 - ₹170.26.
Is BALPHARMA undervalued or overvalued?
Based on our multi-method analysis, Bal Pharma (BALPHARMA) appears to be trading above calculated value by approximately 48.1%.
BALPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Bal Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.03 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.89x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BALPHARMA Cash Flow Quality — Operating & Free Cash Flow
Bal Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹20 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹23 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-2 Cr | ₹-13 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹27 Cr | ₹22 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹22 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |